In addition, NCEH1, ABCG5, and ABCG8 are reported to be drug targets of pioglitazone [43] and ezetimibe [42] in the therapy of human gallbladder cholesterolosis and HFD-induced fatty liver. Here, NCEH1 is linked to fatty liver disease.